NeuroBo Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q3 2024.
  • NeuroBo Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $139K, a 19.2% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $478K, a 40.6% increase year-over-year.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $222K, a 74% decline from 2022.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $854K, a 29% increase from 2021.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $662K, a 5.29% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $478K $139K -$33K -19.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $511K $135K +$111K +463% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $400K $104K +$178K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $222K $100K -$118K -54.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $340K $172K -$46K -21.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $386K $24K -$187K -88.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $573K -$74K -$281K -136% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $854K $218K +$30K +16% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $824K $218K +$111K +104% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $713K $211K +$31K +17.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $682K $207K +$20K +10.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $662K $188K +$28K +17.5% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-31
Q3 2021 $634K $107K -$102K -48.8% Jul 1, 2021 Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $736K $180K +$9K +5.26% Apr 1, 2021 Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $727K $187K +$28K +17.6% Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $699K $160K +$235K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $464K $209K +$155K +287% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $309K $171K +$92K +116% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $217K $159K +$99K +165% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $118K -$75K -$650K -113% Oct 1, 2019 Dec 31, 2019 10-K 2021-04-15
Q3 2019 $768K $54K -$1.57M -96.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $2.34M $79K -$830K -91.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $3.17M $60K -$960K -94.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20
Q4 2018 $4.13M $575K -$163K -22.1% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-18
Q3 2018 $4.29M $1.63M +$891K +121% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $3.4M $909K -$2.05M -69.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $5.46M $1.02M +$184K +22% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $5.27M $738K -$195K -20.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $5.47M $736K +$169K +29.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $5.3M $2.96M +$2.87M +3019% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $2.43M $836K +$713K +580% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $1.72M $933K Oct 1, 2016 Dec 31, 2016 10-K 2019-03-18
Q3 2016 $567K +$473K +503% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $95K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $123K +$59K +92.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $94K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-02
Q1 2015 $64K Jan 1, 2015 Mar 31, 2015 10-Q 2016-09-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.